About Merz NeurosciencesMerz Neurosciences is a division of Merz North America and is deeply committed to offering novel therapeutic options that address the largely unmet medical needs that exist within the area of neuroscience. Merz Neurosciences is an important contributor to the U.S. neurosciences space and offers a portfolio that includes the neurotoxin Xeomin® (incobotulinumtoxinA), the anticholinergic Cuvposa® (glycopyrrolate) Oral Solution and the Prolaryn® injectable implant family of products. To learn more about Merz Neurosciences and their U.S. product portfolio, please visit www.merzusa.com/neurosciences.
2 articles with Merz Neurosciences
Merz Neurosciences announced that the U.S. Food and Drug Administration approved a treatment for chronic drooling in adults.
Merz Neurosciences To Present XEOMIN (Incobotulinumtoxina) Data At The 21st International Congress Of Parkinson’s Disease And Movement Disorders